A Phase I, Open-Label Absorption, Distribution, Metabolism, and Excretion (ADME) Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Vismodegib (Primary) ; Vismodegib (Primary)
- Indications Basal cell cancer; Brain cancer; Colorectal cancer; Ovarian cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 22 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 22 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2009 New trial record